On April 15, 2019, BIOTRONIK received FDA approval to transition the ongoing Protego DF4 Post Approval Registry to a new EP PASSION real-world data methodology.

The purpose of this registry study is to confirm the long-term safety and reliability of the Protego DF4 right ventricular lead.

Inclusion Criteria:

• Implanted within the last 30 days or candidate for implantation of a BIOTRONIK ICD or CRT-D DF4 compatible system along with the Protego DF4 lead
• Meets ICD or CRT-D system implant recommendations as defined in guidelines published by relevant professional societies
• Able to understand the nature of the registry and provide informed consent
• Available for follow-up visits on a regular basis at the investigational site for the expected 5 years of follow-up
• Age greater than or equal to 18 years

Exclusion Criteria:

• Enrolled in any investigational cardiac device trial
• Planned cardiac surgical procedures or interventional measures within the next 6 months
• Expected to receive heart transplantation or ventricular assist device within 1 year
• Life expectancy of less than 1 year
• Presence of another life-threatening, underlying illness separate from their cardiac disorder
• Patients reporting pregnancy at the time of enrollment

The patients selected for participation should be from the investigators' general patient population according to the inclusion and exclusion criteria.